Company environment · Oral FDC · NMPA / CDE
Oral fixed-dose combination NMPA / CDE deficiency response
Under NMPA / CDE review; 80-day supplementary-data deficiency clock active.
1What does this company do?
Pharmaceutical sponsor responding to a China NMPA / CDE supplementary-data deficiency notice for an oral fixed-dose combination (FDC) tablet.
2Where is the product on its way to patients?
Multi-strength oral fixed-dose combination tablet under China CDE technical review.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- The product is here
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
3What is happening right now?
The CDE supplementary-data deficiency notice has issued, starting the 80-day statutory response clock.
4Tasks
6 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →